ArticleJournal of gastroenterology and hepatology2021

Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease.

Katsuyoshi Matsuoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.